South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 .
Bibliographical noteThis is the peer reviewed version of the following article: Hanif, W., Ali, S., Bellary, S., Patel, V., Farooqi, A., Karamat, M.A., Saeed, M., Sivaprasad, S., Patel, K. and Khunti, K. (2020), Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Diabetic Medicine. Accepted Author Manuscript e14497., which has been published in final form at https://doi.org/10.1111/dme.14497. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
- South Asians
- cardiovascular disease
- cardiovascular outcome trials
- glucagon-like peptide-1 receptor agonists
- practice guidelines
- sodium-glucose transporter 2 inhibitors
- type 2 diabetes